Quantification of methylone and metabolites in rat and human plasma by liquid chromatography-tandem mass spectrometry

被引:8
|
作者
Ellefsen, Kayla N. [1 ,2 ]
Concheiro, Marta [1 ]
Suzuki, Masaki [3 ,4 ]
Rice, Kenner C. [3 ,4 ]
Elmore, Joshua S. [5 ]
Baumann, Michael H. [5 ]
Huestis, Marilyn A. [1 ]
机构
[1] NIDA, Chem & Drug Metab, Intramural Res Program, NIH, Baltimore, MD 21224 USA
[2] Univ Maryland, Toxicol Program, Baltimore, MD 21201 USA
[3] NIDA, Drug Design & Synth Sect, Intramural Res Program, Baltimore, MD 21224 USA
[4] NIAAA, NIH, Baltimore, MD USA
[5] NIDA, Designer Drug Res Unit, Intramural Res Program, NIH, Baltimore, MD 21224 USA
基金
美国国家卫生研究院;
关键词
Methylone; Synthetic cathinones; Novel designer drugs; Metabolites; 4-Hydroxy-3-methoxymethcathinone; LC-MS/MS; SYNTHETIC CATHINONES; DESIGNER DRUG; BATH SALTS; MEPHEDRONE; MDPV;
D O I
10.1007/s11419-015-0263-z
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Methylone is a commonly abused synthetic cathinone derivative marketed as a "legal" alternative to "ecstasy" or cocaine. Previous studies examined the metabolism of methylone in vitro and in vivo; 4-hydroxy-3-methoxymethcathinone (HMMC) was identified as the primary metabolite, with other reported minor metabolites, 3,4-methylenedioxycathinone (MDC) and 3,4-dihydroxymethcathinone (HHMC). However, limited information is known about methylone and its metabolites' pharmacokinetics. We developed and fully validated a method for the simultaneous quantification of methylone, HMMC, MDC and HHMC by liquid chromatography-tandem mass spectrometry in 100 A mu l rat and human plasma. beta-Glucuronidase was utilized for plasma hydrolysis, followed by perchloric acid protein precipitation and solid-phase extraction utilizing cation exchange columns. Chromatographic separation was performed with a Synergi Polar column in gradient mode, and analytes were determined by two multiple reaction monitoring (MRM) transitions. Linear ranges of 0.5-1,000 A mu g/l (methylone, HMMC and MDC) and 10-1,000 A mu g/l (HHMC) were achieved. Bias and imprecision were generally acceptable, although quantification of HHMC exhibited variability (16.2-37 %). Extraction efficiencies and ion suppression were 89.9-104 % (for HHMC, 15.9-16.2 %) and < 11.4 %, respectively. Methylone and metabolites were stable in plasma for 24 h at room temperature, 72 h at 4 A degrees C, and after three freeze-thaw cycles (except for a 60 % HMMC increase). Human and rat plasma were cross-validated, documenting that rat plasma quality control samples were accurately quantified against a human plasma calibration curve (-23.8 to 12 % bias). As proof of method, rat plasma specimens were analyzed pre-injection and after subcutaneous administration of methylone at 6 mg/kg from 15 to 480 min post-dosing. Methylone, HMMC, MDC and HHMC concentrations ranged from 1.1 to 1,310, 11.2 to 194, 1.9 to 152 and 24.7 to 188 A mu g/l, respectively.
引用
收藏
页码:202 / 212
页数:11
相关论文
共 50 条
  • [21] Sensitive liquid chromatography-tandem mass spectrometry method for quantification of hydrochlorothiazide in human plasma
    Ramakrishna, NVS
    Vishwottam, KN
    Manoj, S
    Koteshwara, M
    Wishu, S
    Varma, DP
    BIOMEDICAL CHROMATOGRAPHY, 2005, 19 (10) : 751 - 760
  • [22] Quantification of Human Plasma-Busulfan Concentration by Liquid Chromatography-Tandem Mass Spectrometry
    Moon, Soo Young
    Lim, Min Kyoo
    Hong, Susie
    Jeon, Yongbum
    Han, Minje
    Song, Sang Hoon
    Lim, Kyoung Soo
    Yu, Kyung-Sang
    Jang, In-Jin
    Lee, Ji Won
    Kang, Hyoung Jin
    Song, Junghan
    ANNALS OF LABORATORY MEDICINE, 2014, 34 (01) : 7 - 14
  • [23] Quantification of Fluoxetine in Human Plasma by the Development of Liquid Chromatography-tandem Mass Spectrometry Method
    Negi, Geeta
    Majeed, Jaseela
    Arora, Saurabh
    Rana, Sachin
    Singh, Manoj
    Tomar, Jaideep
    INDIAN JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH, 2021, 55 (01) : S303 - S311
  • [24] A liquid chromatography-tandem mass spectrometry assay for quantification of rilpivirine and dolutegravir in human plasma
    Gregoire, M.
    Deslandes, G.
    Renaud, C.
    Bouquie, R.
    Allavena, C.
    Raffi, F.
    Jolliet, P.
    Dailly, E.
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2014, 971 : 1 - 9
  • [25] Quantification of metronidazole in human bile fluid and plasma by liquid chromatography-tandem mass spectrometry
    Yoon, Jimin
    Kang, Sung Wook
    Shim, Wang-Seob
    Lee, Jun Kyu
    Jang, Dong Kee
    Gu, Namyi
    Kim, Sae Kyul
    Lee, Kyung-Tae
    Chung, Eun Kyoung
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2020, 1138
  • [26] Rapid liquid chromatography-tandem mass spectrometry method for quantification of ziprasidone in human plasma
    Al-Dirbashi, OY
    Aboul-Enein, HY
    Al-Odaib, A
    Jacob, M
    Rashed, MS
    BIOMEDICAL CHROMATOGRAPHY, 2006, 20 (04) : 365 - 368
  • [27] A validated method for the quantification of fosfomycin in human plasma by liquid chromatography-tandem mass spectrometry
    Martens-Lobenhoffer, Jens
    Bode-Boeger, Stefanie M.
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2015, 990 : 164 - 168
  • [28] Quantification of human plasma-busulfan concentration by Liquid Chromatography-Tandem Mass Spectrometry
    Jebabli, N.
    Baazaoui, B. Z. N.
    Gaies, E.
    El Jebari, H. E. J.
    Charfi, C. H. R.
    Salouage, I. S.
    Daghfous, R. D.
    Trabelsi, S. T.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 165 - 165
  • [29] Simultaneous quantification of amiloride and hydrochlorothiazide in human plasma by liquid chromatography-tandem mass spectrometry
    Shah, Jaivik V.
    Shah, Priyanka A.
    Sanyal, Mallika
    Shrivastav, Pranav S.
    JOURNAL OF PHARMACEUTICAL ANALYSIS, 2017, 7 (05) : 288 - 296
  • [30] Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry
    Jourdil, Jean-Francois
    Nemoz, Benjamin
    Gautier-Veyret, Elodie
    Romero, Charlotte
    Stanke-Labesque, Francoise
    THERAPEUTIC DRUG MONITORING, 2018, 40 (04) : 417 - 424